Dec 31, 2023

Lantheus Q4 2023 Earnings Report

Lantheus reported record revenues, earnings, cash flows, and patient impact, advancing its position as the leading radiopharmaceutical-focused company.

Key Takeaways

Lantheus Holdings, Inc. reported a strong Q4 2023 with worldwide revenue of $354.0 million, a 34.5% increase compared to Q4 2022. GAAP net income was $103.4 million, or $1.47 per fully diluted share, compared to a net loss in the prior year. Adjusted fully diluted EPS was $1.75, a 28.0% increase year-over-year. Free cash flow was $100.2 million.

Worldwide revenue for Q4 2023 reached $354.0 million, including a $15.0 million RELISTOR milestone.

GAAP net income for Q4 2023 was $103.4 million, or $1.47 per fully diluted share.

Adjusted fully diluted EPS for Q4 2023 was $1.75, a 28.0% increase compared to Q4 2022.

Free cash flow for Q4 2023 was $100.2 million.

Total Revenue
$354M
Previous year: $263M
+34.5%
EPS
$1.75
Previous year: $1.37
+27.7%
Gross Profit
$230M
Previous year: $167M
+37.5%
Cash and Equivalents
$714M
Previous year: $416M
+71.7%
Free Cash Flow
$100M
Previous year: $101M
-0.4%
Total Assets
$1.65B
Previous year: $1.32B
+25.0%

Lantheus

Lantheus

Lantheus Revenue by Segment

Forward Guidance

The Company provides its guidance for the first quarter and full year 2024 as follows: 1Q 2024 Revenue $347 million - $355 million 1Q 2024 Adjusted Fully Diluted EPS $1.50 - $1.54 FY 2024 Revenue $1.41 billion - $1.445 billion FY 2024 Adjusted Fully Diluted EPS $6.50 - $6.70